Economic Cost of Lung Cancer Management in the Oncology Department of Sidi Bel Abbes | ||
| Bulletin of Pharmaceutical Sciences Assiut University | ||
| Articles in Press, Accepted Manuscript, Available Online from 18 November 2025 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bfsa.2025.387164.2568 | ||
| Authors | ||
| Dalila MIRAOUI* 1; Abderrahmane BOULERIEL2; Fatéma BECHIR3; Derouicha MATMOUR4; Mounia SAKOUHI4; Djamila YEKROU4 | ||
| 1Medical Oncology Department, Aboubekr Belkaid University; Tlemcen 13000; TOXICOMED Laboratory | ||
| 2Pharmacy Department, Batna University, Batna, 05000, Algeria | ||
| 3Pharmacy Department, Algies University, Algies 16000, Algeria | ||
| 4Djillali LIABES University , Sidi Bel Abbes 22000, Algeria | ||
| Abstract | ||
| Introduction: Lung cancer represents a public health issue, requiring a substantial budget for its management. Objectives: The objective was to estimate the direct costs of drug-based management of lung cancer in the Sidi Bel Abbes province (Algeria). Method: A descriptive retrospective study was conducted from January 1, 2022, to December 31, 2022, to estimate the direct cost of lung cancer management. The hospital pricing method was used. Results: Seventy-nine patients with lung cancer were included. The average age was 62.6 ± 5.6 years. Four patients (2.5%) underwent pneumonectomy surgeries, six patients received either concomitant or sequential radio-chemotherapy, and 54 patients were treated with medical therapy (chemotherapy, targeted therapy). In total, 270 treatment cycles were administered, with an average of 4.9 cycles per patient. The total cost of lung cancer management was 51,519,131.42 DZD (352,870.76 EUR), with an average cost per patient of 652,140.90 ± 23,663.56 DZD (4,453.71 ± 162.06 EUR). Conclusion: The overall economic cost of lung cancer management in Algeria is a complex issue. Investments in prevention, early detection, palliative care, and innovative treatments could help reduce the financial burden in the long term. However, several challenges persist, including unequal access to quality care and the high cost of imported medications and medical equipment. | ||
| Keywords | ||
| cancer; lung; treatment; economic cost | ||
|
Statistics Article View: 4 |
||
